- Home
- Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme
Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme
- Heart Failure
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
This on-demand programme, Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme, has been developed to further education among practicing cardiologists to ensure understanding of the latest developments in reverse cardiac remodelling in heart failure, how emerging data relates to current practice in Malaysia, and is intended to support the application of current understanding of treatment strategies for heart failure, and the role of cardiac remodelling, biomarkers, and provide a review of trials and latest data..
The programme brings together a leading international faculty from Malaysian, US, UK, and Italy, for a seven-part series.
Endorsement
This programme is endorsed by the National Heart Association to promote quality cardiovascular care through education.
Support
This programme is supported by an unrestricted educational grant from Novartis. Novartis had no involvement in the organisation of the programme.
Disclosure
In compliance with Malaysian Medical Association (MMA) guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CPD activities.
This programme is supported by an unrestricted educational grant from Novartis. The scientific programme has not been influenced in any way by the sponsor.
Faculty Disclosures
Dato’ Dr David Chew
- No conflicts of interest to declare pertaining to this programme.
Dr James Januzzi
- Grant support from Novartis Pharmaceuticals, Applied Therapeutics, and Innolife
- Consulting income from Abbott Diagnostics, Janssen, Novartis, Quidel and Roche Diagnostics
- Clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, CVRx, Janssen, MyoKardia, and Takeda
- Trustee, American College of Cardiology
Dr Akshay Desai
- Received consulting fees from Abbott, Alnylam, AstraZeneca, Biofourmis, Boston Scientific, Boehringer-Ingelheim, DalCor Pharma, Merck, Novartis, Relypsa, Regeneron and Research Grants from AstraZeneca, Alnylam, and Novartis
Prof Andrew Coats
- No conflicts of interest to declare pertaining to this programme.
Dr Michele Senni
- Financial interest for consultancy with: Novartis, Merck, Bayer, Vifor Pharma, Abbott, Boehringer Ingelheim, Astra-Zeneca, Bioventrix, Servier
Dr Pardeep Jhund
- No conflicts of interest to declare pertaining to this programme.
Terms & Conditions
Radcliffe Education requires contributors to our CME/CPD programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
This programme ‘Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice’ is accredited by the Malaysian Medical Association (MMA) for 1 hour of external CPD credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity.
Instructions to Participants
There is no fee for taking part in this online learning activity.
Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Target Audience
- Cardiologists, heart failure specialists, allied health professionals, and GPs with a specialist interest in heart failure.
Learning Objectives
- Define cardiac remodelling, with particular focus on the influence of cardiovascular damage, pathogenic risk factors and the structural and functional changes in the left ventricle.
- List the main clinical implications of cardiac remodelling.
- Summarise the relationship between circulating biomarkers, such as NT-proBNP, troponin and sST2, with the extent left ventricular remodelling in subjects with HF.
- Interpret the most recent clinical data from pharmacological and device-based studies in HFrEF and HfpEF.
- Recall the evidence for reverse cardiac remodelling brought about through ARNi therapy, including (but not limited to) PROVE-HF and EVALUATE-HF.
- Review real-world insight into the impact that ARNi therapy has on cardiac reverse remodelling.
Recognising and Treating Cardiac Remodelling in Heart Failure
Duration:
Speakers: James L Januzzi (Harvard Medical School, Cambridge, US) David Chew (Cardiac Vascular Sentral Kuala Lumpur, Malaysia)
The Clinical Implications of Cardiac Remodelling in Heart Failure
Duration:
Speakers: Akshay S Desai (Brigham and Women’s Hospital, Boston, US) David Chew (Cardiac Vascular Sentral Kuala Lumpur, Malaysia)
Relationship of Cardiac Biomarkers
Duration:
Speakers: James L Januzzi (Harvard Medical School, Cambridge, US) Akshay S Desai (Brigham and Women’s Hospital, Boston, US) David Chew (Cardiac Vascular Sentral Kuala Lumpur, Malaysia)
Prevalence of HFpEF on the Rise – Treat HFpEF as a Whole, Not Just the Comorbidities
Duration:
Speakers: Andrew JS Coats (University of Warwick, UK) David Chew (Cardiac Vascular Sentral Kuala Lumpur, Malaysia)
ARNI: PARAMOUNT, PARAGON-HF, PARALLAX and Putative Placebo Analysis
Duration:
Speakers: Michele Senni (Bergamo, IT) David Chew (Cardiac Vascular Sentral Kuala Lumpur, Malaysia)
Overview of the Evidence
Duration:
Speakers: Andrew JS Coats (University of Warwick, UK) Michele Senni (Bergamo, IT) David Chew (Cardiac Vascular Sentral Kuala Lumpur, Malaysia)
Angiotensin Receptor Neprilysin Inhibitors – Renal Safety and Efficacy
Duration:
Speakers: Pardeep Jhund (University of Glasgow, UK) David Chew (Cardiac Vascular Sentral Kuala Lumpur, Malaysia)
This programme accredited by the Malaysian Medical Association (MMA) for 1 external CPD credit. Once the course is completed, there are instructions on how to receive your credit.
Related Courses
- Not accredited
Published:
Learning objectives
- Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
- Apply latest guideline recommendations to patient cases
- Describe barriers preventing early initiation of GDMT
- Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
- Identify the importance of the nurse/cross-functional team
- 1.00
Published:
Learning objectives
- To differentiate ATTR phenotypes based on presenting signs and symptoms.
- To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
- To recall how to identify disease progression across ATTR-cm.
- To describe the different disease modifying treatments for ATTR including novel agents.
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
- 1.00
Published:
Learning objectives
- Review current GDMT in HFrEF and HFpEF
- Describe the relationship between initiation of GDMT and HF outcomes
- Prescribe GDMT according to current international recommendations
- Recall the elements of the Kansas City Cardiomyopathy Questionnaire
- Describe the clinical studies that support the use of functional and QoL measures in practice
- Initiate quality of life and functional improvement measures in routine practice
- Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
- Adopt shared decision-making with HF patients
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
- 1.00
Published:
Learning objectives
- Recall the results of key trials in HFmrEF in different patients' sub-groups
- Describe how SGLT-2 inhibitors can be used across the range of LVEF
- Apply emerging diagnostic approaches for HFpEF and HFmrEF
- Implement best-practice strategies across the range of LVEF
- Not accredited
Published:
Learning objectives
- Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
- Recall current inertia rates amongst prescribers who manage heart failure
- Adopt effective treatment strategies for HFpEF patients early in the disease course
- Recall current guideline directed medical therapy options in HFpEF
- Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF